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ABSTRACT 
 
Background – DMSO is routinely infused together with hematopoietic cells in 
patients undergoing myeloablative therapy and was recently found to inhibit 
smooth muscle cells proliferation and arterial thrombus formation in the 
mouse by preventing tissue factor (TF), a key activator of the coagulation 
cascade. This study was designed to investigate whether DMSO prevents 
platelet activation and thus, whether it may represent an interesting agent to 
be used on drug eluting stents.  
Methods and Results – Human venous blood from healthy volunteers was 
collected in citrated tubes and platelet activation was studied by cone and 
platelet analyzer (CPA) and Rapid-Platelet-Function-Assay (RPFA). CPA 
analysis showed that DMSO-treated platelets exhibit a lower adherence in 
response to shear stress (-15.54 ± 0.9427 %, n = 5, P<0.0001 versus control). 
Additionally, aggregometry studies revealed that DMSO-treated, 
arachidonate-stimulated platelets had an increased lag phase (18.0 % ± 4.031 
n = 9, P = 0.0004, versus control) as well as a decreased maximal 
aggregation (-6.388 ± 2.212 %, n = 6, P = 0.0162 versus control). Inhibitory 
action of DMSO could be rescued by exogenous thromboxane A2 and was 
mediated, at least in part, by COX-1 inhibition.   
Conclusions – Clinically relevant concentrations of DMSO impair platelet 
activation by a thromboxane A2-dependent, COX-1-mediated effect. This 
finding may be crucial for the previously reported anti-thrombotic property 
displayed by DMSO. Our findings support a role for DMSO as a novel drug to 
prevent not only proliferation, but also thrombotic complications of drug eluting 
stents. 
 
Key words: Platelet activation – thrombosis – drug eluting stents 
2 
 
Introduction 
 
Arterial thrombosis is the crucial event in a large number of cardiovascular 
conditions such as acute coronary syndromes (ACS) [6, 19]. Even though 
coronary bare metal stents (BMS) and drug-eluting stent (DES) implantation 
greatly improved prognosis of ACS patients, acute and sub-acute stent 
thrombosis still remain a serious concern [4, 5, 14, 15, 17, 20, 31, 34]. In line 
with this, we recently showed that drugs released from DES enhance tissue 
factor (TF), a key trigger for thrombosis and thus could play a paradoxical role 
in eliciting stent thrombosis [29, 32]. In this context, DMSO could represent an 
interesting alternative drug which not only inhibits human vascular smooth 
muscle cell (HVSMC) proliferation, but also prevents TF expression and 
thrombus formation in vivo [6].  
Initiation of a luminal thrombosis involves both activation of the coagulation 
cascade by TF and factor VII [18, 22, 23, 33], and platelet activation [13, 26]. 
Under normal circumstances, platelets do not aggregate spontaneously; 
however, in the event of an injury, platelets adhere to the disrupted surface 
and release different biologically active substances which induce aggregation 
[13]. Abnormal platelet activation is implicated in a wide variety of 
cardiovascular disorders [1, 3, 16, 20, 28, 36] and is also thought to be 
important in atherogenesis [3]. Anti-platelet therapy is an increasingly 
important aspect of secondary prevention in patients suffering from 
cardiovascular disease and especially in those who underwent DES 
implantation [20, 35]. Discovery of novel agents capable of simultaneously 
preventing restenosis, thrombosis and platelet activation would offer an 
unprecedented opportunity to develop improved DES.  
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In light of its previously reported properties including inhibition of HVSMC 
proliferation and TF-mediated thrombosis [6, 8], we investigated whether 
DMSO inhibits platelet activation and thus exerts its strong anti-thrombotic 
properties via a combined inhibitory effect. 
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Material and Methods 
 
Study protocol 
Citrated venous blood samples were drawn from healthy adult volunteers who 
had not taken medications known to affect platelet function for at least one 
week before blood sampling. Thirty ml of venous blood were drawn into a 
plastic syringe containing trisodium citrate (0.129 M). For cone and platelet 
analyzer experiments, 200 l of whole blood were used; for aggregometry 
experiments, 225 l of platelet rich plasma (PRP) at a concentration of 
250’000 platelets/ml were used. In DMSO experiments, samples were pre-
treated with DMSO 0.5% (6.3 mM) for 30 minutes.  
 
Cone and platelet analyzer 
To study platelet activation under shear stress conditions, CPA test was 
performed as previously described [10]. Briefly, 200 µL of citrated blood were 
placed in polystyrene wells and circulated at a high shear rate (1875 s–1) for 2 
minutes with a rotating Teflon cone. Wells were then washed with PBS, 
stained with May-Grünwald dye, and analyzed with an inverted-light 
microscope connected to an image analysis system. Results are expressed as 
percentage of the total well surface covered by platelets.  
 
Aggregometry & rapid-platelet-function-assay  
The Rapid-Platelet-Function-Assay (RPFA) is a semiquantitative platelet 
function test which measures turbidometric platelet aggregation as an 
increase of light transmittance due to platelet agglutination [25]. The test was 
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performed according to the manufacturer’s instructions. The RPFA reports 
results in "platelet aggregation units," a function of the rate at which platelets 
aggregate.  
Briefly, turbidometric platelet aggregation was performed in platelet-rich 
plasma (250 x 103 cells/mm3) and aggregation was assessed as maximal 
aggregation at 6 minutes after adding the agonist. Platelet aggregation was 
measured following stimulation with: arachidonate (2mM), ADP (10-5-1.25 
M), collagen (10-5-1.25g/ml), ristocetin (1.25-0.62 mg/ml), U46619 (3 M) 
or epinephrine (10-5-1.25 M) in the presence or absence of DMSO 0.5% (6.3 
mM) preincubation 30 minutes before stimulation with the agonist. 
 
Cyclooxygenase activity assay 
Cyclooxygenase (COX) activity in response to vehicle (PBS) or DMSO 0.5% 
(6.3 mM) treatment was determined in PRP as peroxydise activity (Cayman 
chemical kit no. 760151, MI, USA). Generation of N,N,N’,-tetramethyl-p-
phenylenediamine (TMPD) was measured colorimetrically at 590 nm. The 
assay was performed following the supplier’s indications. Briefly, 1.5 ml of 
PRP (250’000 platelets/ml) was lysed in EDTA 1 mM and tris-HCL 0.1 M at 
pH 7.8 for 10 minutes by mechanical grinding. Samples were then centrifuged 
for 10 minutes at 14000 rpm at 4°C and resuspended in 150 l of the same 
buffer. COX-1 specific inhibitor SC-560 and COX-2 specific inhibitor DuP-697 
were used to identify which COX isoform is inhibited by DMSO.  
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Statistical analysis 
Data are presented as mean+SD. For the comparison of two groups, unpaired 
Student’s t-test and Mann–Whitney test were applied for normally and non-
normally distributed variables, respectively. ANOVA with Bonferroni’s 
correction was used for comparison of greater than or equal to three groups. 
A P-value<0.05 was considered significant. 
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Results 
 
DMSO inhibits platelet adherence 
Exposure to shear stress (1875 s–1) for 2 minutes triggered platelet activation 
and high rate platelet adherence (Fig 1, upper panel). In control vehicle 
treated platelets, the area covered by the adhering platelets equalled 19.00 ± 
0.6919 %, (n = 5) of the total dish surface. In samples pretreated with DMSO 
0.5% (6.3 Mm) for 30 minutes, the area covered by adhering platelets 
drastically decreased to 3.465 ± 0.2656  %, n = 5, P < 0.0001 (Fig 1). 
CPA is a validated technique also for the assessment of shear stress-induced 
platelet aggregation [27]. Following shear stress average platelet aggregate 
size in control conditions equalled 38.28 ± 7.440 (n = 5) and decreased to 
8.926 ± 0.4291 (n = 5, P = 0.0254) in DMSO treated samples (data not 
shown). 
 
DMSO delays and decreases maximal platelet aggregation 
Aggregometry studies were performed on human PRP in response to several 
agonists. Time to aggregation (lag-phase) was significantly increased (18.0 % 
± 4.031, n = 9, P = 0.0004) by DMSO pretreatment in arachidonate- (2mM) 
stimulated platelets (Fig 2A), but not in ADP- (10-5, 1.25 M), collagen- (10-5, 
1.25g/ml), ristocentin- (1.25, 0.62 mg/ml), U46619- (3 M)  or epinephrine- 
(10-5, 1.25 M) stimulated platelets (Table 1, upper panel). Additionally, 
DMSO pretreatment significantly decreased maximal aggregation in response 
to arachidonate by 6.388 % ± 2.212 (n = 6, P = 0.0162, Fig 2B). In contrast, 
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aggregation in response to other agonists was not affected by DMSO (Table 
1, lower panel). 
To investigate whether the inhibitory action of DMSO could be rescued by 
exogenous thromboxane A2, platelets were incubated with the thromboxane-
A2 analogue U46619. Platelet stimulation with U46619 (3 M) alone triggered 
comparable maximal aggregation to arachidonate (2 mM) (n = 6, P = NS, Fig 
2B). Co-incubation of U46619 with DMSO could restore arachidonate-
stimulated maximal platelet aggregation (n = 6, P = 0.0162, Fig 2B). 
 
DMSO inhibits platelet aggregation via COX-1 
To find out whether the effect of DMSO on platelet aggregation was caused 
by an inhibited COX activity, COX-dependent peroxydise activity was 
determined. Incubation of PRP with DMSO 0.5% (6.3 Mm) for 30 minutes 
significantly decreased total COX activity by 36.23 % ± 15.31 (n = 5, P = 
0.0455) compared to control (Fig 3). Similarly, incubation of PRP with the 
COX-1 specific inhibitor SC-560 caused a comparable inhibition of total COX 
activity by 33.65 % ± 10.16 (n = 5, P = 0.0107) compared to control. Co-
incubation of DMSO and SC-560 caused no further decrease in COX activity 
compared to control and DMSO alone thus indicating that the residual COX 
activity is represented by COX-2 and that DMSO acts via inhibition of COX-1 
(Fig 3). 
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Discussion 
 
The present study demonstrates that 0.5% (6.3 mM) DMSO strongly inhibits 
platelet shear stress-induced adherence of human platelets. Additionally, 
DMSO prolongs lag phase and decreases maximal aggregation of human 
platelets in response to arachidonate but not to ADP, collagen, epinephrine 
and ristocetin. This finding underscores the specificity of the effect observed 
with DMSO. The inhibitory effect of DMSO could be prevented by exogenous 
thromboxane A2 and is mediated, at least in part, by inhibition of COX-1. 
In patients undergoing myeloablative therapy, DMSO is infused intravenously 
together with hematopoietic progenitor cells with plasma concentrations 
readings of 1.6% (20.0 mmol/L) and only rarely causes adverse effects [9]; 
thus, the concentrations used in this study are well within clinically relevant 
levels. Furthermore, in previous in vitro studies we have shown that DMSO 
concentrations up to 1% are not toxic for human endothelial cells, smooth 
muscle cells and peripheral blood monocytes [6].  
DMSO was previously suggested to inhibit platelet activation; however, this 
was postulated only indirectly and without any molecular insights [6, 8]. In this 
study, we for the first time can clearly demonstrate that DMSO inhibits platelet 
adherence and platelet aggregation which are essential steps for the 
physiological and pathophysiological formation of a stable occlusive thrombus 
[24]. Thrombus formation is the key process in stent thrombosis, a rare but 
serious complication observed following DES deployment [30, 31]. 
Furthermore, platelet activation is also a relevant contributing factor in the 
regulation of tissue factor (TF) expression [7] – the key regulator of the 
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coagulation cascade. In fact, platelets were shown to not only lead to the 
formation of the primary plug, but also suggested to contribute to the 
triggering of thrombin generation, fibrin deposition and clot consolidation [21]. 
Findings from the present study reinforce the concept that DMSO is an 
interesting alternative for the coating of DES where currently employed drugs 
do not completely address the risks of stent thrombosis [4, 5, 14, 15, 17, 20, 
31, 34] and, in addition, were shown to induce the expression of TF [29, 32, 
38]. 
Formation of an occlusive thrombus is a dynamic processes which requires a 
coordinated series of events involving the coagulation system, the fibrinolytic 
system and platelet activation [26]. Thus, delaying platelet activation can 
impair thrombus formation by disturbing the timing required for the 
coordinated action of the above cited systems [11]. Besides inhibiting 
arachidonate-induced maximal platelet aggregation, DMSO also prolonged 
lag phase. This finding could offer an elegant additional explanation to 
previous observations where DMSO-treated mice showed a permanent 
dynamic state of thrombus formation and lysis but failed to develop stable 
occlusive thrombi following laser injury [6]. 
The exogenous thromboxane A2 analogue U46619 prevented the inhibitory 
effect of DMSO on platelet aggregation implying that DMSO alters the release 
of prothrombotic thromboxane A2. Thromboxane A2 is a potent platelet 
activating eicosanoid synthetised from COX-dependent endoperoxides [2] and 
its inhibition has been proposed as a novel approach to prevent stent 
thrombosis [37]. To identify the possible mediator of altered thromboxane A2 
levels, total COX activity was assayed. COX-1, but not COX-2 activity was 
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shown to be significantly decreased by DMSO treatment hence revealing that 
DMSO impairs arachidonate-induced platelet aggregation via inhibition of 
COX-1. 
In conclusion, the present study offers new evidence for the suitability of 
DMSO as a potential new drug to be used in DES. Presently available DES 
have efficiently addressed the problem of VSMC-mediated restenosis; 
however, stent-thrombosis remains a serious concern [12, 30, 31]. 
Accordingly, current clinical guidelines recommend prolonged periods of 
systemic dual antiplatelet therapy with obviously increased risks of bleeding 
complications.  As a platelet inhibitor DMSO eluting stents could allow a 
simplified local antiaggregant treatment protocol in DES patients thereby 
reducing systemic treatment associated risks and costs [20, 35]. Through its 
dual mechanism of action DMSO may represent an interesting novel agent for 
DES capable of preventing both restenosis and thrombotic complications 
simultaneously.  
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Figure and Table Legend 
 
Figure 1: DMSO inhibits shear stress-induced platelet adherence. 
Upper panel) Shear stress induces platelet activation and adherence to the 
polystyrene surface of the cell culture dish (left). Treatment with DMSO (right) 
strongly inhibits adherence of activated platelets. Adhering platelets are 
visualised by May-Grünwald staining. 
Lower panel) Histogram showing quantification of adhering platelets without 
(clear bar) and with (black bar) DMSO treatment, N = 5, P < 0.0001 versus 
control. 
.  
Figure 2: DMSO delays platelet activation and decreases maximal 
platelet aggregation 
A) DMSO pretreatment (black bar) significantly increased time to aggregation 
(lag-phase) in arachidonate-stimulated platelets, N = 9, P = 0.0004 versus 
control. 
B) Arachidonate(ara)-induced platelet aggregation was blunted by DMSO 
treatment and U46619 stimulated comparable aggregation to ara. 
Coincubation of U46619 with DMSO prevented the inhibitory effect of DMSO 
N = 6, P = N.S. versus ara. 
 
Figure 3: DMSO inhibits COX-1 activity 
DMSO 0.5% significantly decreased total COX activity N = 5, P = 0.0455 
compared to control. Similarly, COX-1 inhibitor SC-560 caused a comparable 
inhibition of total COX activity N = 5, P = 0.0107 compared to control. Co-
incubation of DMSO and SC-560 caused no further decrease in COX activity 
N = 5, P = N.S. compared to DMSO alone. 
 
Table 1: Lag-phase and maximal aggregation in response to other 
agnists than arachidonate is unaffected by DMSO.  
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